ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits

Today's Daily Dose brings you news about how the third time proved to be a charm for Adamis Pharma's Epinephrine Pre-filled Syringe; favorable Markman claim construction ruling for Oxford Immunotec; encouraging results from Lilly's phase III trial of Taltz in patients with active psoriatic arthritis, dubbed SPIRIT-P2, and Skyline Medical's STREAMWAY System securing the CE Mark.

from RTT - Biotech http://ift.tt/2svhUAK
via IFTTT